Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 13
2004 20
2005 21
2006 16
2007 10
2008 16
2009 16
2010 17
2011 25
2012 24
2013 14
2014 14
2015 6
2016 13
2017 16
2018 10
2019 19
2020 19
2021 19
2022 18
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
Kawano Y, Kim K, Min CK, Koh Y, Ishizawa K, Kim SH, Ito S, Tanaka J, Uchiyama M, Ishida T, Kim JS, Moreau P, Martin T, Tada K, Risse ML, Suzuki K. Kawano Y, et al. Among authors: tanaka j. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e360-e367. doi: 10.1016/j.clml.2023.06.011. Epub 2023 Jul 3. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37479547 Free article. Clinical Trial.
CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia.
Akahoshi Y, Nakasone H, Takenaka K, Yamasaki S, Nakamura M, Doki N, Tanaka M, Ozawa Y, Uchida N, Ara T, Nakamae H, Ota S, Onizuka M, Yano S, Tanaka J, Fukuda T, Kanda Y, Atsuta Y, Kako S, Yanada M, Arai Y. Akahoshi Y, et al. Among authors: tanaka j. Blood Adv. 2023 Jun 27;7(12):2699-2708. doi: 10.1182/bloodadvances.2022009376. Blood Adv. 2023. PMID: 36661335 Free PMC article.
Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?
Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, Katayama Y, Tanaka M, Ueda Y, Onizuka M, Miyakoshi S, Ozawa Y, Fukuda T, Matsuoka KI, Tanaka J, Kimura T, Ichinohe T, Atsuta Y. Konuma T, et al. Among authors: tanaka j. Bone Marrow Transplant. 2023 Aug;58(8):893-906. doi: 10.1038/s41409-023-01997-3. Epub 2023 May 8. Bone Marrow Transplant. 2023. PMID: 37156881 Free PMC article.
[Hematopoietic cell transplantation in Japan: nationwide survey 2013].
Kurata M, Yanagisawa A, Atsuta Y, Sakamaki H, Kato K, Ichinohe T, Tanaka J, Hirokawa M, Adachi S, Inoue M, Kikuchi A, Yabe H, Kawa K, Sawada A, Mori S, Morishima Y, Kato S, Nagamura T, Matsumoto K, Suzuki R, Nakao S, Takanashi M, Kodera Y, Okamoto S. Kurata M, et al. Among authors: tanaka j. Rinsho Ketsueki. 2014 Dec;55(12):2381-99. doi: 10.11406/rinketsu.55.2381. Rinsho Ketsueki. 2014. PMID: 25744039 Review. Japanese. No abstract available.
Reactivation of hepatitis B virus with rituximab.
Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N. Tsutsumi Y, et al. Among authors: tanaka j. Expert Opin Drug Saf. 2005 May;4(3):599-608. doi: 10.1517/14740338.4.3.599. Expert Opin Drug Saf. 2005. PMID: 15934864 Review.
305 results